An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs CA-4948 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Curis
- 18 Jan 2018 Status changed from not yet recruiting to recruiting.
- 07 Nov 2017 According to a Curis media release, this trial is expected to begin in the fourth quarter of 2017.
- 03 Nov 2017 New trial record